Perfluoroalkyl (RF) titanocene reagents [Cp2Ti(III)RF] synthesized via [Cp2Ti(III)Cl] rather than [Cp2Ti(II)] show new types of perfluoroalkylation reactions. The [Cp2Ti(III)RF] reagents exhibit a wide variety of reactivity with carbonyl compounds including esters and nitriles, and selectivities far higher than those reported for conventional RFLi and RFMgX reagents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/chem.201303089 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Alzheimer's disease (AD) remains a formidable neurodegenerative challenge, characterized by profound cognitive decline. Despite decades of research, effective disease-modifying therapies are elusive. Recent advances in molecular neuropharmacology have unveiled potential therapeutic targets for AD, offering renewed hope.
View Article and Find Full Text PDFBackground: Understanding the fundamental differences between the human and pre-human brain is a prerequisite for designing meaningful models and therapies for AD. Expressed CHRFAM7A, a human restricted gene with carrier frequency of 75% in the human population predicts profound translational significance.
Method: The physiological role of CHRFAM7A in human brain is explored using multiomics approach on 600 post mortem human brain tissue samples (ROSMAP).
Dementia Care Practice.
Alzheimers Dement
December 2024
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Introduction: Lecanemab (LEQEMBI®), a humanized monoclonal antibody targeting Amyloid-beta (Aβ) protofibrils, received full FDA approval in July 2023 for treating early-stage Alzheimer's disease (AD). This abstract highlights Tel Aviv Medical Center's (TLVMC) specialized infrastructure for early AD diagnosis and treatment and includes presenting baseline characteristics of initial patients opting for LEQEMBI®.
Methods: Outlining our clinics' operational experience in establishing the Center for advanced treatments for AD, treatment protocol, and a descriptive analysis of baseline assessment data including demographics, baseline Magnetic-Resonance-Imaging (MRI), Cerebrospinal-fluid (CSF)/PET biomarkers, pre-treatment cognitive evaluations (Mini-Mental-State-Examination (MMSE)/Montreal-Cognitive-Assessment (MoCA)), and Apolipoprotein-E (APOE) status.
Dementia Care Practice.
Alzheimers Dement
December 2024
Kentucky College of Osteopathic Medicine, PikeVille, KY, USA.
This perspective abstract highlights the critical demand for culturally sensitive technology in dementia caregiving due to the heightened risk and unique challenges faced by individuals from diverse backgrounds. The escalating prevalence of dementia necessitates a caregiving paradigm shift, especially in the context of diverse cultural backgrounds. Research consistently underscores the existence of cultural disparities in dementia risk, diagnosis, and care outcomes, emphasizing the urgent need for culturally sensitive technology in dementia care.
View Article and Find Full Text PDFTechnology and Dementia Preconference.
Alzheimers Dement
December 2024
Kentucky College of Osteopathic Medicine, PikeVille, KY, USA.
This perspective abstract highlights the critical demand for culturally sensitive technology in dementia caregiving due to the heightened risk and unique challenges faced by individuals from diverse backgrounds. The escalating prevalence of dementia necessitates a caregiving paradigm shift, especially in the context of diverse cultural backgrounds. Research consistently underscores the existence of cultural disparities in dementia risk, diagnosis, and care outcomes, emphasizing the urgent need for culturally sensitive technology in dementia care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!